SOURCE-LINKED STUDY SUMMARY
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Abstract summarizedQuality not appraised
- What was studied
- A randomized phase 2 trial tested daily subcutaneous liraglutide versus placebo for non-alcoholic steatohepatitis over the treatment period.
- Who / model studied
- Adults with overweight and clinical NASH were randomized to liraglutide or placebo; end-of-treatment biopsies were available for participants in both groups.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- NASH resolution was more common with liraglutide than placebo, while fibrosis progression was less common. Gastrointestinal events were frequent in both groups.
- Limitations & context
- The biopsy analysis included fewer participants than the randomized groups, and the authors called for longer studies.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(15)00803-x